Aprea Therapeutics, Inc. Retained Earnings
Aprea Therapeutics, Inc. (APRE) had Retained Earnings of -$340.52 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-12
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$340.52M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$336.93M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$333.64M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$331.19M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$340.52M 10-Q · filed 2026-08-12 |
| 2026-03-31 | -$336.93M 10-Q · filed 2026-05-13 |
| 2025-12-31 | -$333.64M 10-Q · filed 2026-08-12 |
| 2025-09-30 | -$331.19M 10-Q · filed 2025-11-12 |
| 2025-06-30 | -$328.21M 10-Q · filed 2025-08-12 |
| 2025-03-31 | -$324.97M 10-Q · filed 2025-05-14 |
| 2024-12-31 | -$321.04M 10-K · filed 2026-03-16 |
| 2024-09-30 | -$318.15M 10-Q · filed 2024-11-07 |
| 2024-06-30 | -$314.36M 10-Q · filed 2024-08-12 |
| 2024-03-31 | -$310.89M 10-Q · filed 2024-05-14 |
| 2023-12-31 | -$308.08M 10-K · filed 2025-03-25 |
| 2023-09-30 | -$304.64M 10-Q · filed 2023-11-09 |
| 2023-06-30 | -$301.44M 10-Q · filed 2023-08-10 |
| 2023-03-31 | -$298.18M 10-Q · filed 2023-05-15 |
| 2022-12-31 | -$293.80M 10-K · filed 2024-03-26 |
| 2022-09-30 | -$291.35M 10-Q · filed 2022-11-09 |
| 2022-06-30 | -$287.33M 10-Q · filed 2022-08-12 |
| 2022-03-31 | -$189.07M 10-Q · filed 2022-05-16 |
| 2021-12-31 | -$181.13M 10-K · filed 2023-03-30 |
| 2021-09-30 | -$173.38M 10-Q · filed 2021-11-08 |
| 2021-06-30 | -$163.93M 10-Q · filed 2021-08-12 |
| 2021-03-31 | -$153.68M 10-Q · filed 2021-05-06 |
| 2020-12-31 | -$144.01M 10-K · filed 2022-03-15 |
| 2020-09-30 | -$128.61M 10-Q · filed 2020-11-06 |
| 2020-06-30 | -$116.30M 10-Q · filed 2020-08-11 |
| 2020-03-31 | -$99.93M 10-Q · filed 2020-05-15 |
| 2019-12-31 | -$90.53M 10-K · filed 2021-03-16 |
| 2019-09-30 | -$77.46M 10-Q · filed 2019-11-14 |
| 2018-12-31 | -$62.47M 10-K · filed 2020-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |